Polyethylenimine-based iron oxide nanoparticles enhance cisplatin toxicity in ovarian cancer cells in the presence of a static magnetic field.
cell responses
cisplatin
cytotoxicity
magnetic iron oxide nanoparticles
polyethylenimine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
05
2023
accepted:
28
08
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Drug resistance in cancer cells is a major concern in chemotherapy. Cisplatin (CIS) is one of the most effective chemotherapeutics for ovarian cancer. Here, we investigated an experimental approach to increase CIS cytotoxicity and overcome cell resistance using nanoparticle-based combination treatments. Polyethylenimine (PEI)-based magnetic iron oxide nanocomplexes were used for drug delivery in genetically matched CIS-resistant (A2780/CP) and -sensitive (A2780) ovarian cancer cells in the presence of a 20 mT static magnetic field. Magnetic nanoparticles (MNPs) were synthesized and bonded to PEI cationic polymers to form binary complexes (PM). The binding of CIS to the PM binary complexes resulted in the formation of ternary complexes PM/C (PEI-MNP/CIS) and PMC (PEI-MNP-CIS). CIS cytotoxicity increased at different concentrations of CIS and PEI in all binary and ternary delivery systems over time. Additionally, CIS induced cell cycle arrest in the S and G2/M phases and reactive oxygen species production in both cell lines. Ternary complexes were more effective than binary complexes at promoting apoptosis in the treated cells. PEI-based magnetic nanocomplexes can be considered novel carriers for increasing CIS cytotoxicity and likely overcoming drug resistance of ovarian cancer cells.
Sections du résumé
Background
UNASSIGNED
Drug resistance in cancer cells is a major concern in chemotherapy. Cisplatin (CIS) is one of the most effective chemotherapeutics for ovarian cancer. Here, we investigated an experimental approach to increase CIS cytotoxicity and overcome cell resistance using nanoparticle-based combination treatments.
Methods
UNASSIGNED
Polyethylenimine (PEI)-based magnetic iron oxide nanocomplexes were used for drug delivery in genetically matched CIS-resistant (A2780/CP) and -sensitive (A2780) ovarian cancer cells in the presence of a 20 mT static magnetic field. Magnetic nanoparticles (MNPs) were synthesized and bonded to PEI cationic polymers to form binary complexes (PM). The binding of CIS to the PM binary complexes resulted in the formation of ternary complexes PM/C (PEI-MNP/CIS) and PMC (PEI-MNP-CIS).
Results
UNASSIGNED
CIS cytotoxicity increased at different concentrations of CIS and PEI in all binary and ternary delivery systems over time. Additionally, CIS induced cell cycle arrest in the S and G2/M phases and reactive oxygen species production in both cell lines. Ternary complexes were more effective than binary complexes at promoting apoptosis in the treated cells.
Conclusion
UNASSIGNED
PEI-based magnetic nanocomplexes can be considered novel carriers for increasing CIS cytotoxicity and likely overcoming drug resistance of ovarian cancer cells.
Identifiants
pubmed: 37771439
doi: 10.3389/fonc.2023.1217800
pmc: PMC10522916
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1217800Informations de copyright
Copyright © 2023 Ashoori, Hajipour-Verdom, Satari and Abdolmaleki.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiat Res. 2022 Oct 1;198(4):384-395
pubmed: 35867630
Chem Biol Interact. 2006 Mar 10;160(1):1-40
pubmed: 16430879
Biochem Pharmacol. 2012 Apr 15;83(8):1104-11
pubmed: 22285912
Biochem Pharmacol. 2002 Jul 15;64(2):191-200
pubmed: 12123739
Nat Protoc. 2006;1(3):1458-61
pubmed: 17406435
Aging (Albany NY). 2023 Mar 20;15(6):1964-1976
pubmed: 36947706
Cell Stress Chaperones. 2016 Jul;21(4):687-96
pubmed: 27117522
Curr Med Chem. 2020;27(34):5675-5715
pubmed: 31419925
Int J Cancer. 2005 Jun 20;115(3):393-402
pubmed: 15688364
Hum Exp Toxicol. 2016 Apr;35(4):377-87
pubmed: 26134983
Drug Resist Updat. 2020 Mar;49:100671
pubmed: 31841768
Mol Cancer Ther. 2008 Oct;7(10):3247-55
pubmed: 18852128
Curr Med Chem. 2003 Feb;10(3):257-66
pubmed: 12570712
Mol Cell. 2008 Jul 25;31(2):167-77
pubmed: 18657500
Drug Resist Updat. 2020 May;50:100683
pubmed: 32146422
J Nucleic Acids. 2010 Aug 08;2010:
pubmed: 20811617
IUBMB Life. 2018 Mar;70(3):183-191
pubmed: 29394468
Math Biosci. 2020 Nov;329:108456
pubmed: 32841615
Int J Radiat Biol. 2019 Aug;95(8):1194-1201
pubmed: 30822212
Cancer Res. 2012 Sep 15;72(18):4616-21
pubmed: 22962276
Thorac Cancer. 2021 Dec;12(24):3340-3355
pubmed: 34741403
J Extracell Vesicles. 2019 Jun 17;8(1):1626654
pubmed: 31258880
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6
pubmed: 19805294
Gene Ther. 2005 Mar;12(5):461-6
pubmed: 15616603
ACS Appl Mater Interfaces. 2019 Sep 4;11(35):31638-31648
pubmed: 31389684
Arch Gynecol Obstet. 2020 May;301(5):1227-1233
pubmed: 32253553
Int J Oncol. 2013 Oct;43(4):1141-50
pubmed: 23917396
Molecules. 2020 Jun 10;25(11):
pubmed: 32532030
Cell Death Dis. 2013 Dec 19;4:e973
pubmed: 24357804
Pharmaceuticals (Basel). 2018 Oct 23;11(4):
pubmed: 30360520
Mol Ther. 2013 Jan;21(1):149-57
pubmed: 23032976
Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):1893-1900
pubmed: 28552631
J Chromatogr B Biomed Appl. 1995 Jul 21;669(2):247-63
pubmed: 7581901
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
pubmed: 7638184
Clin Cancer Res. 2004 Jul 15;10(14):4661-9
pubmed: 15269138
Int J Pharm. 2010 Apr 15;389(1-2):10-7
pubmed: 20060458
Biomaterials. 2012 Feb;33(5):1462-76
pubmed: 22098779
Biomed Res Int. 2013;2013:602987
pubmed: 24027759
J Inorg Biochem. 2002 Apr 28;89(3-4):197-202
pubmed: 12062123
Int J Nanomedicine. 2019 Mar 21;14:1997-2010
pubmed: 30962684
Nanomedicine (Lond). 2012 Jan;7(1):65-78
pubmed: 22191778
PLoS One. 2013 Nov 19;8(11):e81162
pubmed: 24260552
J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302
pubmed: 10944550
Mol Cancer. 2023 Mar 7;22(1):46
pubmed: 36882769
Biopolymers. 2022 Jul;113(7):e23491
pubmed: 35560028
Oncol Rep. 2010 Apr;23(4):965-72
pubmed: 20204280
Chem Biol Interact. 1987 Jan;61(1):1-15
pubmed: 3815585
ACS Nano. 2010 Aug 24;4(8):4539-50
pubmed: 20731437
Met Based Drugs. 2010;2010:
pubmed: 20885916
Semin Cancer Biol. 2021 Dec;77:167-181
pubmed: 32871277
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11
pubmed: 19144690
Int J Cancer. 2001 Nov;94(4):492-9
pubmed: 11745434
Cancer Lett. 2016 Apr 1;373(1):36-44
pubmed: 26801746
Spectrochim Acta A Mol Biomol Spectrosc. 2023 May 15;293:122490
pubmed: 36801738
J Control Release. 2003 Sep 19;92(1-2):199-208
pubmed: 14499197
Sci Rep. 2018 Jan 17;8(1):990
pubmed: 29343746
Cancer Res. 1992 Dec 15;52(24):6885-9
pubmed: 1458477
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Hum Gene Ther. 1996 Oct 20;7(16):1947-54
pubmed: 8930654
Int J Clin Exp Med. 2015 May 15;8(5):6687-701
pubmed: 26221207
Cancer Treat Rev. 2007 Feb;33(1):9-23
pubmed: 17084534